These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

959 related items for PubMed ID: 24967933

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Significant improvement in symptoms, skin test, and specific bronchial reactivity after 6 months of treatment with a depigmented, polymerized extract of Dermatophagoides pteronyssinus and D. farinae.
    Ferrer A, García-Sellés J.
    J Investig Allergol Clin Immunol; 2003; 13(4):244-51. PubMed ID: 14989113
    [Abstract] [Full Text] [Related]

  • 23. Effect of allergen-specific immunotherapy on plasma level of platelet factor 4 (PF-4) and beta-thromboglobulin (beta-TG), platelet activation markers in patients with house dust mite allergy.
    Kasperska-Zajac A, Brzoza Z, Rogala B.
    Vaccine; 2007 May 04; 25(18):3595-8. PubMed ID: 17291641
    [Abstract] [Full Text] [Related]

  • 24. Changes in inflammatory and clinical parameters and in bronchial hyperreactivity asthmatic children sensitized to house dust mites following sublingual immunotherapy.
    Silvestri M, Spallarossa D, Battistini E, Sabatini F, Pecora S, Parmiani S, Rossi GA.
    J Investig Allergol Clin Immunol; 2002 May 04; 12(1):52-9. PubMed ID: 12109533
    [Abstract] [Full Text] [Related]

  • 25. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.
    Mosbech H, Canonica GW, Backer V, de Blay F, Klimek L, Broge L, Ljørring C.
    Ann Allergy Asthma Immunol; 2015 Feb 04; 114(2):134-40. PubMed ID: 25624131
    [Abstract] [Full Text] [Related]

  • 26. Correlation of skin test results and specific immunoglobulin E blood levels with nasal provocation testing for house-dust mite allergies.
    Haxel BR, Huppertz T, Boessert P, Bast F, Fruth K.
    Am J Rhinol Allergy; 2016 Feb 04; 30(1):60-4. PubMed ID: 26867532
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study.
    Lue KH, Lin YH, Sun HL, Lu KH, Hsieh JC, Chou MC.
    Pediatr Allergy Immunol; 2006 Sep 04; 17(6):408-15. PubMed ID: 16925685
    [Abstract] [Full Text] [Related]

  • 31. Aqueous intradermal low-dose house dust mite immunotherapy in tropical settings: a valid cost-effective approach for developing nations?
    Rondon C, Sánchez-Borges M, Cupello ER, Fabiano F, Capriles-Hulett A.
    Allergol Immunopathol (Madr); 2021 Sep 04; 49(2):31-39. PubMed ID: 33641291
    [Abstract] [Full Text] [Related]

  • 32. [The results of specific immunotherapy for house dust mites in patients with allergic rhinitis].
    Sahin E, Taş E, Dağtekin Ergür EN, Cuhali BD, Gürsel AO.
    Kulak Burun Bogaz Ihtis Derg; 2008 Sep 04; 18(2):79-84. PubMed ID: 18628641
    [Abstract] [Full Text] [Related]

  • 33. The Dermatophagoides pteronyssinus Molecular Sensitization Profile of Allergic Rhinitis Patients in Central China.
    Yang Y, Zhu R, Huang N, Li W, Zhang W, Wang Y, Yang L.
    Am J Rhinol Allergy; 2018 Sep 04; 32(5):397-403. PubMed ID: 30001632
    [Abstract] [Full Text] [Related]

  • 34. A DNA vaccine encoding a chimeric allergen derived from major group 1 allergens of dust mite can be used for specific immunotherapy.
    Sun T, Yin K, Wu LY, Jin WJ, Li Y, Sheng B, Jiang YX.
    Int J Clin Exp Pathol; 2014 Sep 04; 7(9):5473-83. PubMed ID: 25337189
    [Abstract] [Full Text] [Related]

  • 35. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M, Eifan AO, Keles S, Akkoc T, Nursoy MA, Bahceciler NN, Barlan IB.
    Respir Med; 2013 Sep 04; 107(9):1322-9. PubMed ID: 23886432
    [Abstract] [Full Text] [Related]

  • 36. A novel microcrystalline tyrosine-adsorbed, mite-allergoid subcutaneous immunotherapy: 1-year follow-up report.
    Roger A, Depreux N, Jurgens Y, Serra AT, Heath MD, Garcia G, Skinner MA.
    Immunotherapy; 2016 Oct 04; 8(10):1169-74. PubMed ID: 27388990
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Specific immunotherapy for rhinitis and asthma with a subcutaneous hypoallergenic high-dose house dust mite extract: results of a 9-month therapy.
    El-Qutob D, Moreno F, Subtil-Rodríguez A.
    Immunotherapy; 2016 Jul 04; 8(8):867-76. PubMed ID: 27188493
    [Abstract] [Full Text] [Related]

  • 39. [Mite sensitization in children followed for respiratory allergy in a tropical African environment in Cotonou, Benin].
    Agodokpessi G, Sagbo G, Bigot C, Hountohotegbe T, Dossou-Yovo S, Djogbessi D, Bigot A.
    Rev Mal Respir; 2019 Feb 04; 36(2):135-141. PubMed ID: 30686558
    [Abstract] [Full Text] [Related]

  • 40. Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis.
    Zhang L, Wang C, Han D, Wang X, Zhao Y, Liu J.
    Int Arch Allergy Immunol; 2009 Feb 04; 148(2):161-9. PubMed ID: 18802361
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 48.